Buscar
01/06/2026
Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.
Broto, JM, Terés, R, Marquina, G, Perez-Fidalgo, JA, Lopez-Jimenez, C, Alonso-Romero, JL, Redondo, A, Gutierrez, A, Casado, A, Sebio, A, Ledesma, P, Merino-Garcia, JA, Mayordomo, E, Moura, DS, Hindi, N. Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11572. PMID:. IF:41.900(Q1/1D).
01/06/2026
Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial
Mondaza-Hernandez, JL, Moura, DS, Redondo, A, Sebio, A, Beveridge, RD, Martínez-Trufero, J, Romero-Gonzalez, P, Shirikova, A, Rodriguez, C, Carrera, M, Lopez-Jimenez, C, Hindi, N, Broto, JM. Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23520. PMID:. IF:41.900(Q1/1D).
01/06/2026
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801
Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04164-w. PMID:41420791. IF:2.500(Q3/6D).
01/06/2026
Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).
Montañá, JR, Roselló, S, Paez, D, Safont, MJ, Vidal, J, Gravalos, C, Polo, E, Jimenez-Fonseca, P, Calle, SG, Paredes, BG, Beltran, M, Gonzalo-Ruiz, J, Rosales, C, Palmer, HG, Garcia, DL, Nuciforo, P, Vivancos-Prellezo, A, Tabernero, J, Elez, E. Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.TPS3681. PMID:. IF:41.900(Q1/1D).